Your AI-Trained Oncology Knowledge Connection!

Geoffrey Y. Ku, MD

Articles

Dr. Ku on the Efficacy of Zanidatamab Plus Chemotherapy in HER2+ Gastroesophageal Adenocarcinoma

February 11th 2022

Geoffrey Y. Ku, MD, medical oncologist, discusses the efficacy of zanidatamab plus standard chemotherapy in patients with HER2-positive gastroesophageal adenocarcinoma in the ongoing phase 2 ZW25-201 trial.

Dr. Ku on Evaluating Zanidatamab Plus Chemotherapy in HER2-Expressing GEA

Geoffrey Y. Ku, MD

October 27th 2021

Geoffrey Y. Ku, MD, discusses the rationale to evaluate zanidatamab in combination with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma.

Dr. Ku on Role of Durvalumab in Gastric Cancer

Geoffrey Y. Ku, MD

April 24th 2019

Geoffrey Y. Ku, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of durvalumab in the treatment of patients with gastric cancer.

Dr. Ku on Immunotherapy in Gastric and Esophageal Cancer

Geoffrey Y. Ku, MD

February 9th 2017

Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center discusses immunotherapy treatments for patients with gastric and esophageal cancers.

Dr. Ku on Combinations and Sequencing of Treatments for Gastric Cancer

Geoffrey Y. Ku, MD

January 24th 2017

Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses combinations of treatments for patients with gastric and esophageal cancers.